[go: up one dir, main page]

AR050914A1 - Agonista receptor de vasopresina peptidico - Google Patents

Agonista receptor de vasopresina peptidico

Info

Publication number
AR050914A1
AR050914A1 ARP050103332A ARP050103332A AR050914A1 AR 050914 A1 AR050914 A1 AR 050914A1 AR P050103332 A ARP050103332 A AR P050103332A AR P050103332 A ARP050103332 A AR P050103332A AR 050914 A1 AR050914 A1 AR 050914A1
Authority
AR
Argentina
Prior art keywords
vasopresine
peptidic
receptor agonist
compounds
treatment
Prior art date
Application number
ARP050103332A
Other languages
English (en)
Inventor
Kazimierz Wisniewski
Claudio Schteingart
Regent Laporte
Robert Felix Galyean
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of AR050914A1 publication Critical patent/AR050914A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/16—Oxytocins; Vasopressins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

El presente se relaciona con los compuestos novel, composiciones farmacéuticas de compuestos utilizados para la elaboracion de un medicamento para el tratamiento de las condiciones del shock inter alia como también de un método para el tratamiento de tales condiciones, donde tales compuestos son administrados. Los compuestos son presentados por la formula general (1).
ARP050103332A 2004-08-11 2005-08-11 Agonista receptor de vasopresina peptidico AR050914A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04019029 2004-08-11

Publications (1)

Publication Number Publication Date
AR050914A1 true AR050914A1 (es) 2006-12-06

Family

ID=34926126

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050103332A AR050914A1 (es) 2004-08-11 2005-08-11 Agonista receptor de vasopresina peptidico

Country Status (25)

Country Link
US (2) US8148319B2 (es)
EP (1) EP1776133B1 (es)
JP (1) JP4664363B2 (es)
KR (1) KR100884323B1 (es)
CN (1) CN1964732B (es)
AR (1) AR050914A1 (es)
AT (1) ATE509944T1 (es)
AU (1) AU2005274070B2 (es)
BR (1) BRPI0511466B8 (es)
CA (1) CA2567797C (es)
DK (1) DK1776133T3 (es)
ES (1) ES2366702T3 (es)
IL (1) IL178690A (es)
JO (1) JO2937B1 (es)
MX (1) MX2007001396A (es)
NO (1) NO342449B1 (es)
NZ (1) NZ550707A (es)
PL (1) PL1776133T3 (es)
PT (1) PT1776133E (es)
RU (1) RU2355701C2 (es)
SA (1) SA05260254B1 (es)
SI (1) SI1776133T1 (es)
TW (1) TWI364291B (es)
WO (1) WO2006020491A1 (es)
ZA (1) ZA200700772B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2937B1 (en) * 2004-08-11 2016-03-15 فيرينغ.بي.في Tight muscles of the peptide vascular tensioner receptor
RU2415149C2 (ru) * 2006-02-10 2011-03-27 Ферринг Б.В. Пептидные соединения
ES2566143T3 (es) * 2006-02-13 2016-04-11 Ferring B.V. Uso de agonistas peptídicos de receptor de vasopresina
WO2009037586A2 (en) * 2007-08-14 2009-03-26 Ferring B.V. Use of peptidic vasopressin receptor agonists
ES2629131T3 (es) 2008-09-17 2017-08-07 Chiasma Inc. Composiciones farmacéuticas y métodos de suministro relacionados.
JO3109B1 (ar) * 2012-05-10 2017-09-20 Ferring Bv منبهات لمستقبلات v1a
US9388214B2 (en) * 2014-11-05 2016-07-12 Ferring B.V. V1A receptor agonists
RU2634272C1 (ru) * 2016-08-10 2017-10-24 Закрытое акционерное общество "Санкт-Петербургский институт фармации" Композиция с дезамино-аргинин-вазотоцином для парентерального введения и способ её получения
IL265761B2 (en) 2016-10-21 2024-11-01 Amryt Endo Inc Oral terlipressin compositions for use in treatment of ascites
US11033601B2 (en) 2017-09-14 2021-06-15 The Regents Of The University Of Colorado, A Body Corporate Selective inhibition of V1b for treating fatty liver
CN109748950B (zh) * 2017-11-02 2020-10-30 深圳翰宇药业股份有限公司 一种固相合成血管升压素受体肽激动剂selepressin的方法
EP3517543B1 (en) * 2018-01-30 2020-11-04 Bachem AG Manufacture of glucagon peptides
EP3880226A1 (en) 2018-11-15 2021-09-22 Ferring B.V. Compounds, compositions and methods for treating sepsis
KR20230041029A (ko) * 2020-07-17 2023-03-23 파마인 코포레이션 V1a 수용체 부분 효능제 및 이용 방법
CN120265306A (zh) * 2022-09-30 2025-07-04 辉凌公司 调节平均动脉压的混合型血管加压素受体激动剂-拮抗剂

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE651400A (es) 1963-04-05 1965-02-04
NL129421C (es) 1963-08-30 1900-01-01
CS235151B1 (cs) 1982-08-26 1985-05-15 Michal Lebl Způsob dělení Dal isomerů analogů oxytocinu
US4829051A (en) 1983-04-05 1989-05-09 Vega Laboratories, Inc. N-substituted derivatives of 1-desaminovasopressin
US4483794A (en) 1983-05-10 1984-11-20 Ceskoslovenska Akademie Ved Analogs of neurohypophysial hormones
CS242062B1 (cs) 1984-08-23 1986-04-17 Milan Zaoral Vasopresinová a vasotocinová analoga a způsob jejich přípravy
SE457055B (sv) 1986-08-18 1988-11-28 Ferring Ab Topisk straalskyddsgel foer mukosa innehaallande kaerlsammandragande substanser
SE469473B (sv) 1987-10-07 1993-07-12 Ferring Ab Vasoaktiva peptider
SE502644C2 (sv) * 1990-02-27 1995-11-27 Ferring Ab Vasoaktiva vasotocinderivat
RU2063979C1 (ru) 1992-02-24 1996-07-20 Всесоюзный научно-исследовательский институт технологии кровезаменителей и гормональных препаратов Пептиды последовательности окситоцина
US5516795A (en) * 1994-09-12 1996-05-14 Abbott Laboratories Heteroatom substituted propanyl derivatives having 5-lipoxygenase inhibitory activity
RU2073010C1 (ru) * 1994-10-26 1997-02-10 Российско-германское совместное предприятие "Константа" Способ синтеза лизин-вазопрессина в растворе
GB9617021D0 (en) 1996-08-13 1996-09-25 Salpep Biotechnology Inc Novel peptides for treatment of inflammation and shock
SE9701162D0 (sv) 1997-03-27 1997-03-27 Karolinska Innovations Ab New use II
SE9701161D0 (sv) 1997-03-27 1997-03-27 Karolinska Innovations Ab New use I
WO1999013092A1 (en) 1997-09-11 1999-03-18 The Public Health Research Institute Of The City Of New York, Inc. Enhancement of mucosal antibody responses by interleukin-6
CA2321026A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
SE0001440D0 (sv) 2000-04-18 2000-04-18 Entretech Medical Ab A drug against climacteric disorders
WO2002064740A2 (en) 2001-02-09 2002-08-22 Cognetix, Inc. Cone snail peptides
AU2003220919A1 (en) 2002-03-29 2003-10-13 Wakamoto Pharmaceutical Co., Ltd. Drugs for increasing lacrimal fluid
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
CA2500831A1 (en) 2002-10-03 2004-04-15 Eric Hollander Treatment of autism and similar disorders
CA2557520C (en) 2003-02-26 2011-09-13 Donald W. Landry A method for stabilizing blood pressure in hemodialysis subjects
JO2937B1 (en) * 2004-08-11 2016-03-15 فيرينغ.بي.في Tight muscles of the peptide vascular tensioner receptor
RU2415149C2 (ru) * 2006-02-10 2011-03-27 Ферринг Б.В. Пептидные соединения
ES2566143T3 (es) * 2006-02-13 2016-04-11 Ferring B.V. Uso de agonistas peptídicos de receptor de vasopresina
US8148349B2 (en) 2006-12-20 2012-04-03 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection
RU2342949C1 (ru) 2007-03-26 2009-01-10 Юрий Георгиевич Жуковский Применение [дезамино-1, изолейцин-3, аргинин-8]вазопрессина в качестве средства для увеличения выведения почкой солей натрия и усиления обратного избирательного всасывания из почечных канальцев в кровь воды-растворителя

Also Published As

Publication number Publication date
JP2008509221A (ja) 2008-03-27
JP4664363B2 (ja) 2011-04-06
NO20071314L (no) 2007-05-10
CA2567797C (en) 2012-07-10
DK1776133T3 (da) 2011-07-18
CN1964732A (zh) 2007-05-16
IL178690A0 (en) 2007-02-11
KR100884323B1 (ko) 2009-02-18
CN1964732B (zh) 2011-03-02
BRPI0511466B8 (pt) 2021-05-25
ES2366702T3 (es) 2011-10-24
PT1776133E (pt) 2011-09-02
SA05260254B1 (ar) 2008-05-19
US20120196808A1 (en) 2012-08-02
AU2005274070B2 (en) 2008-02-07
KR20070029183A (ko) 2007-03-13
RU2355701C2 (ru) 2009-05-20
RU2007101238A (ru) 2008-09-20
CA2567797A1 (en) 2006-02-23
US8148319B2 (en) 2012-04-03
SI1776133T1 (sl) 2011-07-29
ATE509944T1 (de) 2011-06-15
HK1100280A1 (en) 2007-09-14
PL1776133T3 (pl) 2011-09-30
TWI364291B (en) 2012-05-21
EP1776133A4 (en) 2008-12-31
ZA200700772B (en) 2008-09-25
JO2937B1 (en) 2016-03-15
EP1776133B1 (en) 2011-05-18
BRPI0511466B1 (pt) 2018-01-23
AU2005274070A1 (en) 2006-02-23
US8778881B2 (en) 2014-07-15
IL178690A (en) 2013-10-31
EP1776133A1 (en) 2007-04-25
US20090054309A1 (en) 2009-02-26
NO342449B1 (no) 2018-05-22
WO2006020491A1 (en) 2006-02-23
NZ550707A (en) 2010-07-30
BRPI0511466A (pt) 2007-12-26
MX2007001396A (es) 2007-04-19
TW200612976A (en) 2006-05-01

Similar Documents

Publication Publication Date Title
AR050914A1 (es) Agonista receptor de vasopresina peptidico
AR065622A1 (es) Derivados de 3-ciano -4- (4-fenil- piperidin -1- il) piridin -2- ona
EA201001595A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
AR069490A1 (es) Agonistas de los receptores de glucocorticoides
ECSP088511A (es) Agonistas del receptor del neuropeptido-2
GT200700103A (es) Compuestos biciclocarboxiamida sustituidos
CR10288A (es) Pirazoles como inhibidores de la 11-beta-hsd1
CO6690768A2 (es) Derivados de triazina-oxadiazoles, útiles como inhibidores de los canales de sodio navi.7
CU24487B1 (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores de gamma ror
EA200970928A1 (ru) Антагонисты рецептора гонадотропин-рилизин-фактора и способы их применения
UY32574A (es) Antagonistas del receptor cxcr3
PE20090890A1 (es) Compuestos derivados de 1-(2,3-dihidrobenzo[1,4]dioxin-2-ilmetil)azaciclos como antagonistas del suptipo adrenoreceptor alfa2c
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
UY28144A1 (es) Agentes terapéuticos
ECSP14013221A (es) Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
MX2020014156A (es) Oxadiazoles como agonistas de los receptores muscarinicos m1 y/o m4.
AR051904A1 (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r)
AR061272A1 (es) Antagonistas de cgrp
CY1113759T1 (el) Ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
CO6430439A2 (es) Agonistas del receptor de esfingosina -1- fosfato
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
CY1113820T1 (el) Παραγωγα 4-αλκοξυπυριδαζινης ως ταχεως διασπομενοι ανταγωνιστες υποδοχεα ντοπαμινης 2
CL2013003646A1 (es) Compuestos derivados de trans-1-(3s.1r)-6-cloro-3-fenilindan-1-il)-1,2,2-trimetilpiperazina deuterados, con actividad en los receptores 5ht2, d1 y d2; proceso de preparacion; compuesto intermediario; composicion y combinacion farmaceutica; y su uso para el tratamiento de la psicosis, entre otros.

Legal Events

Date Code Title Description
FB Suspension of granting procedure